应用负荷后1小时血糖诊断标准显示潜在MASLD的高进展风险。

IF 6.1 3区 医学 Q1 ENDOCRINOLOGY & METABOLISM Diabetes research and clinical practice Pub Date : 2025-02-01 DOI:10.1016/j.diabres.2024.111973
Long Teng , Ling Luo , Yanhong Sun , Wei Wang , Zhi Dong , Xiaopei Cao , Junzhao Ye , Bihui Zhong
{"title":"应用负荷后1小时血糖诊断标准显示潜在MASLD的高进展风险。","authors":"Long Teng ,&nbsp;Ling Luo ,&nbsp;Yanhong Sun ,&nbsp;Wei Wang ,&nbsp;Zhi Dong ,&nbsp;Xiaopei Cao ,&nbsp;Junzhao Ye ,&nbsp;Bihui Zhong","doi":"10.1016/j.diabres.2024.111973","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Recently, a 1-h PG value of ≥ 8.6 mmol/L, a more sensitive predictor of diabetes mellitus-related long-term cardiovascular complications than routine glucose markers, has been recommended as an additional diagnostic criterion for diabetes in the International Diabetes Federation Position Statement. However, its value in MASLD remains uncertain.</div></div><div><h3>Methods</h3><div>Consecutive participants with imaging assessments of fatty liver and a 75-g oral glucose tolerance test, including 1154 participants with MASLD, 161 fulfilling the nonalcoholic fatty liver disease but not the MASLD diagnostic criteria (NAFLD-non-MASLD) and 1026 subjects with non-fatty liver, were retrospectively enrolled from June 2009 to May 2024.</div></div><div><h3>Results</h3><div>Patients with MASLD or NAFLD-non-MASLD had higher 1-h PG levels than those with non-fatty liver (<em>p</em> &lt; 0.001). In patients with MASLD or NAFLD-non-MASLD, 1-h PG ≥ 8.6 mmol/L was associated with the risk of moderate-to-severe steatosis (<em>p</em> &lt; 0.001), ALT elevation (<em>p</em> &lt; 0.001), advanced fibrosis (<em>p</em> = 0.03), and cardiovascular diseases (<em>p</em> &lt; 0.001). Furthermore, NAFLD-non-MASLD patients with 1-h PG ≥ 8.6 mmol/L showed a higher prevalence of advanced fibrosis than MASLD patients with or without 1-h PG ≥ 8.6 mmol/L (<em>p</em> &lt; 0.05).</div></div><div><h3>Conclusions</h3><div>NAFLD-non-MASLD patients with 1-h PG ≥ 8.6 mmol/L are still at high risk of poor clinical outcomes. These findings support including 1-h PG ≥ 8.6 mmol/L as a component of the metabolic dysfunction definition.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"220 ","pages":"Article 111973"},"PeriodicalIF":6.1000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Applying 1-hour postload plasma glucose diagnostic criteria reveals high Progressive Risks of potential MASLD\",\"authors\":\"Long Teng ,&nbsp;Ling Luo ,&nbsp;Yanhong Sun ,&nbsp;Wei Wang ,&nbsp;Zhi Dong ,&nbsp;Xiaopei Cao ,&nbsp;Junzhao Ye ,&nbsp;Bihui Zhong\",\"doi\":\"10.1016/j.diabres.2024.111973\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Recently, a 1-h PG value of ≥ 8.6 mmol/L, a more sensitive predictor of diabetes mellitus-related long-term cardiovascular complications than routine glucose markers, has been recommended as an additional diagnostic criterion for diabetes in the International Diabetes Federation Position Statement. However, its value in MASLD remains uncertain.</div></div><div><h3>Methods</h3><div>Consecutive participants with imaging assessments of fatty liver and a 75-g oral glucose tolerance test, including 1154 participants with MASLD, 161 fulfilling the nonalcoholic fatty liver disease but not the MASLD diagnostic criteria (NAFLD-non-MASLD) and 1026 subjects with non-fatty liver, were retrospectively enrolled from June 2009 to May 2024.</div></div><div><h3>Results</h3><div>Patients with MASLD or NAFLD-non-MASLD had higher 1-h PG levels than those with non-fatty liver (<em>p</em> &lt; 0.001). In patients with MASLD or NAFLD-non-MASLD, 1-h PG ≥ 8.6 mmol/L was associated with the risk of moderate-to-severe steatosis (<em>p</em> &lt; 0.001), ALT elevation (<em>p</em> &lt; 0.001), advanced fibrosis (<em>p</em> = 0.03), and cardiovascular diseases (<em>p</em> &lt; 0.001). Furthermore, NAFLD-non-MASLD patients with 1-h PG ≥ 8.6 mmol/L showed a higher prevalence of advanced fibrosis than MASLD patients with or without 1-h PG ≥ 8.6 mmol/L (<em>p</em> &lt; 0.05).</div></div><div><h3>Conclusions</h3><div>NAFLD-non-MASLD patients with 1-h PG ≥ 8.6 mmol/L are still at high risk of poor clinical outcomes. These findings support including 1-h PG ≥ 8.6 mmol/L as a component of the metabolic dysfunction definition.</div></div>\",\"PeriodicalId\":11249,\"journal\":{\"name\":\"Diabetes research and clinical practice\",\"volume\":\"220 \",\"pages\":\"Article 111973\"},\"PeriodicalIF\":6.1000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes research and clinical practice\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0168822724008830\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes research and clinical practice","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0168822724008830","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

背景:最近,与常规血糖指标相比,1 h PG值≥ 8.6 mmol/L能更灵敏地预测与糖尿病相关的长期心血管并发症,国际糖尿病联盟立场声明建议将其作为糖尿病的附加诊断标准。然而,它在 MASLD 中的价值仍不确定:方法:对2009年6月至2024年5月期间连续接受脂肪肝影像学评估和75克口服葡萄糖耐量试验的患者进行回顾性研究,其中包括1154名MASLD患者、161名符合非酒精性脂肪肝诊断标准但不符合MASLD诊断标准的患者(NAFLD-non-MASLD)和1026名非脂肪肝患者:MASLD或NAFLD-non-MASLD患者的1-h PG水平高于非脂肪肝患者(P1-h PG≥ 8.6 mmol/L的非酒精性脂肪肝-非MASLD患者仍面临不良临床结局的高风险。这些发现支持将 1-h PG ≥ 8.6 mmol/L 作为代谢功能障碍定义的一个组成部分。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Applying 1-hour postload plasma glucose diagnostic criteria reveals high Progressive Risks of potential MASLD

Background

Recently, a 1-h PG value of ≥ 8.6 mmol/L, a more sensitive predictor of diabetes mellitus-related long-term cardiovascular complications than routine glucose markers, has been recommended as an additional diagnostic criterion for diabetes in the International Diabetes Federation Position Statement. However, its value in MASLD remains uncertain.

Methods

Consecutive participants with imaging assessments of fatty liver and a 75-g oral glucose tolerance test, including 1154 participants with MASLD, 161 fulfilling the nonalcoholic fatty liver disease but not the MASLD diagnostic criteria (NAFLD-non-MASLD) and 1026 subjects with non-fatty liver, were retrospectively enrolled from June 2009 to May 2024.

Results

Patients with MASLD or NAFLD-non-MASLD had higher 1-h PG levels than those with non-fatty liver (p < 0.001). In patients with MASLD or NAFLD-non-MASLD, 1-h PG ≥ 8.6 mmol/L was associated with the risk of moderate-to-severe steatosis (p < 0.001), ALT elevation (p < 0.001), advanced fibrosis (p = 0.03), and cardiovascular diseases (p < 0.001). Furthermore, NAFLD-non-MASLD patients with 1-h PG ≥ 8.6 mmol/L showed a higher prevalence of advanced fibrosis than MASLD patients with or without 1-h PG ≥ 8.6 mmol/L (p < 0.05).

Conclusions

NAFLD-non-MASLD patients with 1-h PG ≥ 8.6 mmol/L are still at high risk of poor clinical outcomes. These findings support including 1-h PG ≥ 8.6 mmol/L as a component of the metabolic dysfunction definition.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Diabetes research and clinical practice
Diabetes research and clinical practice 医学-内分泌学与代谢
CiteScore
10.30
自引率
3.90%
发文量
862
审稿时长
32 days
期刊介绍: Diabetes Research and Clinical Practice is an international journal for health-care providers and clinically oriented researchers that publishes high-quality original research articles and expert reviews in diabetes and related areas. The role of the journal is to provide a venue for dissemination of knowledge and discussion of topics related to diabetes clinical research and patient care. Topics of focus include translational science, genetics, immunology, nutrition, psychosocial research, epidemiology, prevention, socio-economic research, complications, new treatments, technologies and therapy.
期刊最新文献
Achievement of guideline targets among people with type 2 diabetes with eASCVD and high risk of ASCVD in the UAE: Results of the PACT-MEA-UAE cohort Acute effects of a single bout structured resistance and combined exercise on blood glucose profile during exercise in patients with type 2 diabetes and healthy adults: A randomized crossover study Effects of exercise training and physical activity advice on HbA1c in people with type 2 diabetes: A network meta-analysis of randomized controlled trials. The effect of multidisciplinary team and experience-based co-design on the care of older adult patients with type 2 diabetes: A randomized controlled trial Editorial Board
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1